Why Do HIV-1 and HIV-2 Use Different Pathways to Develop AZT Resistance?

Paul L Boyer; Stefan G Sarafianos; Patrick K Clark; Eddy Arnold; Stephen H Hughes

doi:10.1371/journal.ppat.0020010

Loading metrics

Open Access

Peer-reviewed

Research Article

Why Do HIV-1 and HIV-2 Use Different Pathways to Develop AZT Resistance?

Paul L Boyer,

Affiliation HIV Drug Resistance Program, NCI-Frederick, Frederick, Maryland, United States of America
⨯
Stefan G Sarafianos,

Affiliation Center for Advanced Biotechnology and Medicine and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, New Jersey, United States of America
⨯
Patrick K Clark,

Affiliation Basic Research Program, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland, United States of America
⨯
Eddy Arnold,

Affiliation Center for Advanced Biotechnology and Medicine and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, New Jersey, United States of America
⨯
Stephen H Hughes

*To whom correspondence should be addressed. E-mail: hughes@ncifcrf.gov

Affiliation HIV Drug Resistance Program, NCI-Frederick, Frederick, Maryland, United States of America
⨯

Why Do HIV-1 and HIV-2 Use Different Pathways to Develop AZT Resistance?

Paul L Boyer,
Stefan G Sarafianos,
Patrick K Clark,
Eddy Arnold,
Stephen H Hughes

Published: February 17, 2006
https://doi.org/10.1371/journal.ppat.0020010

About the Authors

Paul L Boyer

Affiliation HIV Drug Resistance Program, NCI-Frederick, Frederick, Maryland, United States of America

Stefan G Sarafianos

Affiliation Center for Advanced Biotechnology and Medicine and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, New Jersey, United States of America

Patrick K Clark

Affiliation Basic Research Program, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland, United States of America

Eddy Arnold

Affiliation Center for Advanced Biotechnology and Medicine and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, New Jersey, United States of America

Stephen H Hughes

*To whom correspondence should be addressed. E-mail: hughes@ncifcrf.gov

Affiliation HIV Drug Resistance Program, NCI-Frederick, Frederick, Maryland, United States of America

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

PLB, SGS, EA, and SHH conceived and designed the experiments. PLB and SGS performed the experiments. PLB, SGS, EA, and SHH analyzed the data. PKC purified the wild-type and mutant RTs used in the experiments. PLB, SGS, and PKC contributed reagents/materials/analysis tools. PLB, SGS, EA, and SHH wrote the paper.

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

HIV-1
Is the Subject Area "HIV-1" applicable to this article?

Thanks for your feedback.
HIV-2
Is the Subject Area "HIV-2" applicable to this article?

Thanks for your feedback.
Polymerases
Is the Subject Area "Polymerases" applicable to this article?

Thanks for your feedback.
Nucleotides
Is the Subject Area "Nucleotides" applicable to this article?

Thanks for your feedback.
Insertion mutation
Is the Subject Area "Insertion mutation" applicable to this article?

Thanks for your feedback.
Microbial mutation
Is the Subject Area "Microbial mutation" applicable to this article?

Thanks for your feedback.
Hydrogen bonding
Is the Subject Area "Hydrogen bonding" applicable to this article?

Thanks for your feedback.
Polymerization
Is the Subject Area "Polymerization" applicable to this article?

Thanks for your feedback.